The role of the nose in snoring and obstructive sleep apnoea: an update

Abstract

Multilevel anatomic obstruction is often present in snoring and obstructive sleep apnoea (OSA). As the nose is the first anatomical boundary of the upper airway, nasal obstruction may contribute to sleep-disordered breathing (SDB). A number of pathophysiological mechanisms can potentially explain the role of nasal pathology in SDB. These include the Starling resistor model, the unstable oral airway, the nasal ventilatory reflex and the role of nitric oxide (NO). Clinically, a number of case–control studies have shown that nasal obstruction is associated with snoring and mild SDB. However, there is not a linear correlation between the degree of nasal obstruction and the severity of SDB, while nasal obstruction is not the main contributing factor in the majority of patients with moderate to severe OSA. Randomised controlled studies have shown that in patients with allergic rhinitis or non-allergic rhinitis and sleep disturbance, nasal steroids could improve the subjective quality of sleep, and may be useful for patients with mild OSA, however, they are not by themselves an adequate treatment for most OSA patients. Similarly, nasal surgery may improve quality of life and snoring in a subgroup of patients with mild SDB and septal deviation, but it is not an effective treatment for OSA as such. On the other hand, in patients who do not tolerate continuous positive airway pressure (CPAP) well, if upper airway evaluation demonstrates an obstructive nasal passage, nasal airway surgery can improve CPAP compliance and adherence.

Introduction

Hippocrates in “de Morbis Popularibis” (Περί Επιδημιών) noted that nasal polyps were associated with restless sleep [1]. Indeed, most people have experienced sleeping difficulty during episodes of virally induced nasal congestion. Hence, a link between nasal breathing and sleep as well as improvement of sleep quality following relief of nasal obstruction would seem intuitive. However, the literature is not conclusive in that respect despite the interest in the area, as demonstrated by the number of relevant articles published. Nevertheless, our understanding of nasal and sleep physiology and particularly of the importance of nasal and oral breathing as relating to sleep apnoeas and total airway resistance has significantly progressed over the last decade, while recent double-blind randomised controlled trials evaluating treatment outcomes objectively and the use of quality of life (QoL) outcome instruments have further added to our knowledge.

Sleep apnoea is usually defined as cessation of air flow into the lungs which lasts for more than 10 s. The severity of sleep apnoea is defined primarily by the apnoea/hypopnoea index (AHI)—the number of apnoeas (cessation of airflow for more than 10 s) and hypopneas (variable definitions, usually significant decrease in airflow) per hour [2]. Sleep-related breathing disorder (SRBD) is essentially a disease continuum ranging from simple or primary snoring at one end to obstructive sleep apnoea (OSA) at the other [3]. Upper airway resistance syndrome (UARS) occupies an intermediate position in this spectrum. The prevalence of primary/simple snoring in middle-aged men is in the range of 25–50% [4], whereas significant sleep-disordered breathing affects up to 8% of males and 3% of females [5] (as shown in the recent prospective Sleep Heart population study in 6,441 subjects). Dynamic MRI imaging, acoustic analysis, sedation endoscopy and pharyngeal luminal pressure recordings have established the fact that both snoring and OSA are multilevel phenomena [6–10] whereby turbulent airflow is associated with obstruction in the naso, oro and hypopharynx in differing proportions in individual patients. As the nose constitutes the first port of entry of inspired air under normal conditions, nasal pathology has a significant impact on air flow and hence, potentially contribute to SRBD [11, 12].

Effects of nasal obstruction on breathing during sleep

The nose accounts for more than 50% of the total resistance of the upper airway and nasal breathing serves important physiological functions, including humidification, heating and filtration [13]. Physiological mechanisms that explain the relationship between nasal airflow and breathing during sleep include the Starling resistor model, the unstable oral airway proposition, the nasal ventilatory reflex and the role of nitric oxide (NO) (Table 1).

Table 1.

Pathophysiology of nasal function in the pathogenesis of OSA

a. Starling resistor model	Elevated nasal resistance upstream results in increased negative pressure (suction force) in oropharyngeal airway downstream
b. Unstable oral breathing	Significantly increased nasal airway resistance results in compensatory increase of oral breathing fraction and switching to breathing through an unstable oral airway, resulting in increased total airway resistance
c. Nasal-ventilatory reflex	Decreased nasal airflow results in decreased activation of nasal receptors with subsequent inhibitory action on muscle tone, breathing frequency and minute lung ventilation
d. Nitric oxide	Decreased nasal flow results to reduced lung NO with resultant potential perfusion ventilation mismatch as well as various effects on oropharyngeal musculature and arousals

The Starling resistor model [14, 15] (Fig. 1) views the upper airway as a hollow tube, with a partial obstruction at the inlet (corresponding to the nose) and a collapsible segment downstream, corresponding to the oropharynx. This model predicts that a further obstruction upstream (nose) will generate a suction force (negative intraluminal pressure) downstream (oropharynx) resulting, in predisposed individuals, in oropharyngeal collapse. This effect is exacerbated at the supine position, when nasal resistance tends to increase both actively due to postural reflex mechanisms as well as passively as a result of the reduced hydrostatic pressure on nasal venous circulation [16].

Fig. 1.

The Starling resistor model of upper airway collapsibility. The upper airway behaves like a Starling resistor in that obstruction at the inlet (i.e. the nasal airway) produces collapsing forces that are manifest downstream in the collapsible segment, the pharynx

One can argue that this model fails to take into account a major feature of normal breathing, namely oral breathing bypass, the option of mouth breathing when nasal resistance exceeds a certain level. However, this switch (from nasal breathing to oral breathing) is physiologically disadvantageous and results in unstable oral breathing. During sleep, upper airway resistance is lower in subjects breathing through the nose than that through the mouth, unlike awake state, during which upper airway resistance is the same in nasal or oral breathing [17]. Hence, the fraction of oral breathing normally decreases during sleep from 7.6 to 4.3% [18]. When the nasal airway is almost completely obstructed, a switch from nose to mouth breathing occurs, but at a high physiological cost. Mouth breathing is associated with up to 2.5 times higher total resistance [17] and with narrowing of the pharyngeal lumen, decrease in the retroglossal diameter as a result of further posterior retraction of the tongue and increase in the oscillation of the soft palate and redundant pharyngeal tissue [19], all factors leading to SRDB.

A third factor is nasal-ventilator reflex. Experimental application of local anaesthetics to the nasal mucosa of healthy volunteers leads to a significant increase of both central and obstructive apnoeic episodes, of the same magnitude to those reported with complete nasal obstruction [20]. Similar results from other experiments [21] confirmed that the activation of nasal receptors during nasal breathing has a direct positive effect on spontaneous ventilation resulting in higher resting breathing frequency and minute ventilation. Bypassing the nasal airway can lead to reduced nasal receptor activation, deactivation of the nasal-ventilatory reflex and reduced spontaneous ventilation which, in a subset of susceptible individuals can be associated with exacerbating or unmasking previously subclinical sleep apnoea [22], as well as increasing the duration of apnoeic episodes [23].

Finally NO is thought to play a role in maintaining upper airway patency by acting as an aerotransmitter between the nose, pharyngeal musculature and the lung [24]. NO is produced in significant amounts in the nose and sinuses and has been shown to be (and used clinically as) a potent lung vasodilator, reducing perfusion-ventilation mismatch and improving overall blood oxygenation [25]. As the total amount of inspired NO varies accordingly to nasal flow [26], it seems logical that a decrease of nasal ventilation would result in reduced NO delivery to the lungs and a reduced oxygen exchange capability. However, NO has also a role in the maintenance of muscle tone and the regulation of neuromuscular pathways in the pharyngeal musculature as well as spontaneous breathing and sleep regulation, so, overall, its role in the nasal regulation of OSA although probably quite significant, is still not completely understood [27].

Clinical and experimental evidence of correlation between nasal pathology and SDB

Several lines of evidence suggest that experimental reduction of nasal patency and flow has a significant effect on breathing during sleep. In one study, intranasal application of petroleum jelly gauzes in healthy volunteers-induced obstructive apnoeic episodes and resulted in significant increases in AHI, producing frank OSA in one subject [28]. In another study, artificially induced complete or partial nasal obstruction resulted in significant alteration of sleep pattern, with increased micro arousals and total number of apnoeas [29]. In a clinical setting, a number of studies have shown that the application of nasal packs during the management of epistaxis results in significantly worse quality of sleep with multiple apnoeas and desaturation episodes [12, 30–32]. Hence, it is probably safe to conclude that artificially induced partial or complete nasal obstruction results in increased sleep apnoeas.

Nasal obstruction experienced by patients could be due to structural abnormalities (e.g. deviated nasal septum, enlarged turbinates and nasal valve collapse), inflammatory mucosal disease (rhinitis, chronic rhinosinusitis with or without nasal polyps) or more rarely due to neuromuscular problems. Numerous observational studies have demonstrated that nasal congestion is associated with snoring and daytime sleepiness: Wisconsin Sleep Study, a prospective population study of 1,032 healthy volunteers, showed a threefold increased incidence of snoring and day time sleepiness in volunteers with self-reported nocturnal nasal congestion [33], while a study of 37 patients assessed with polysomnography and rhinomanometry showed a correlation between nasal resistance in the supine position and habitual snoring [34]. On the other hand, Lofaso et al. [35] in a prospective study showed that nasal obstruction as documented by posterior rhinomanometry in the awake state is an independent risk factor for OSA, albeit accounting for only 2.3% of the total AHI variance. These results have been contradicted by some other studies including the study by Miljeteig et al. [36], who divided 683 patients referred for sleep polysomnography in three groups, on the basis of their nasal resistance. He subsequently failed to find any differences in apnoea and snoring indices between the three groups [36]. However, the study assessed awake nasal resistance in the erect position, while, as the authors noted themselves, it seems more likely that sleep disturbances correlate with supine nasal obstruction during sleep. The same authors performed a few years later a similar study measuring supine nasal resistance and again failed to find any correlation with Sleep Disturbance indices, however, their study did not include patients with significant nasal obstruction, while all the measurements were done in non-physiologic conditions, with the subjects having their mouths taped (!) throughout the night to prevent oral breathing [37].

Epidemiological studies [38] have shown that allergic rhinitis (AR) affects 9–42% of the population. The mechanism by which allergic rhinitis causes poor sleep quality and daytime fatigue is not entirely clear but it is thought that multiple factors are involved. Apart from nasal obstruction, various inflammatory mediators such as IFN-g, TNF-a, IL-1b, IL-4, and IL-10 [39, 40], postural changes and some therapeutic agents such as antihistamines may also have a direct effect on sleep regulation. In patients with AR a direct association between nasal resistance and SRDB severity has been found [41] as well as between nasal obstruction and subjective quality of sleep and daytime sleepiness [42]. A recent study found that both AR and non-allergic rhinitis (NAR) are associated with impaired sleep quality, with up to 83% of NAR patients having sleep complaints [43].

In a recent overview McNicholas [44] tried to synthesise these apparently conflicting results, pointing out that reversible nasal obstruction maybe more closely associated with SRDB than permanent nasal obstruction, noting that studies assessing patients with temporal obstruction (including iatrogenic and allergic rhinitis) tended to show a more consistent association with SDB than studies assessing patients with structural abnormalities such as deviated nasal septum.

In conclusion, it appears that nasal obstruction, especially reversible, either artificial or disease-induced, is associated with snoring and mild SDB. However, a direct correlation between the degree of nasal obstruction and the severity of SDB has not been found and certainly, nasal obstruction does not appear to be the main contributing factor in the majority of patients with moderate to severe OSA.

Management options

Introduction—problems with research

Nasal pathology associated with nasal obstruction can be treated medically (nasal steroids, antihistamines, decongestants, leukotriene antagonists and nasal dilators) or surgically. Although a number of clinical trials have assessed the effectiveness of the above, they lacked uniformity and only a handful had objective outcome measures. Many of the studies were non-randomised, lacked a control group, had small number of patients and short follow-up periods.

Another problem in many of the studies assessing the efficacy of these treatments, was the lack of clear inclusion criteria. In many studies that was just self-reported nasal obstruction, while in others it was physician’s assessment. On the other hand, the use of objective criteria for nasal obstruction (such as rhinomanometry or acoustic rhinometry) must take into account the unreliable correlation between what these studies measure and what the patient experiences as nasal obstruction. Finally, the results of studies on the effectiveness of medication on nasal pathology (such as allergic rhinitis) assess the effect of treating the underlying disease and not the effect of treating nasal obstruction as such.

Medical treatment

In patients with chronic rhinitis the main cause of high nasal resistance is excessive swelling and engorgement of nasal mucosa. In terms of conservative treatment this could be overcome by topical steroids, sympathomimetic decongestants, or (in the case of AR), by antihistamines and leukotriene antagonists.

Nasal steroids

Randomised trials

There are four double-blind randomised controlled studies assessing the efficacy of nasal steroids on sleep quality in patients with allergic rhinitis [45–48] (Table 2). Only one of these, however, had objective outcome measures and included OSA patients [47], while the other three studies [45, 46, 48] included patients with self-described poor quality of sleep. These three studies were performed using the same methodology, selection criteria and outcomes but with different nasal steroids. Their results have been pooled and presented together by the authors in 2005 [49]. In summary, they showed that patients with Skin Prick Test proven perennial allergic rhinitis had subjective improvement in their quality of sleep as well as reduced daytime sleepiness following treatment with nasal steroids, and this improvement correlated with improvement of nasal patency. In the one [46] where sleep studies were performed they showed no significant change in AHI or any other objectively measured sleep parameter. The fourth trial by Kiely et al. [47] was performed in both NAR and AR patients and also showed improvement in subjective sleep quality in non-OSA patients but not in patients with frank sleep apnoea. Rather contradictorily, it showed a slight reduction of the AHI (by a mean of 6.5 points, from a median of 20 down to 13 episodes per hour), however, most patients continued to have significant OSA.

Table 2.

Randomised controlled studies assessing nasal pharmacological interventions for sleep disturbance

References	Study design	Patients	Nasal pathology	Intervention	Objective outcomes	Subjective outcome	Notes
Kiely et al. [47]	Double blind crossover RCT	10 simple snorers (mean AHI:3), 13 OSA patients (mean AHI: 26.5)	PAR or SAR, no septal deviation	Fluticasone 100 mcg bd for 4 weeks	Median AHI reduced in OSA patients taking fluticasone from 30.3 to 23.0 (p < 0.001)	Improvement daytime alertness for non-apnoeic patients, not for OSA patients	No patient with OSA was cured
Craig et al. [49]	Pooled results from three double blind randomised crossover trials	42 patients with self-reported daytime somnolence and impaired sleep—OSA patients excluded	Subjective nasal obstruction and SPT proven NAR	Nasal steroids od (fluticasone 200 mcg, budesonide 128 mcg, flunisonide 200 mcg) for 3 weeks	Mesured only in fluticasone group: no polysomnographic changes in AHI or other sleep parameters	Decreased sleep problems (1.25 vs. 1.69; p = 0.01), decreased sleepiness (2.89 vs. 3.32; p = 0.02)	Significant correlation between changes in nasal congestion and overall sleep improvement
McLean et al. [51]	Double blind crossover study	Ten OSA patients	Clinician assessed nasal obstruction	Topical xylometazoline (0.2 mg twice) and external dilator strip for one night	AHI reduced by 12, improved sleep architecture	No improvement in daytime sleepiness	No correlation between change in nasal resitance and AHI change. Only one patient had AHI < 15 after treatment
Kerr et al. [50]	Double blind crossover study	10 OSA patients	Six had clinician and patient assessed nasal obstruction	Topical xylometazoline before sleep and internal nasal dilator for one night	No change in AHI, slightly reduced arousal episodes	Subjective improvement in sleep quality
Clarenbach et al. [52]	Double blind crossover study	12 OSA patients	Subjective nasal obstruction	Topical xylometazoline 0.15 mg od before sleep for 1 week	No change in AHI	No improvement in sleep quality	Significant decrease in AHI at the time of maximal decongestion

In conclusion, in patients with AR or NAR and sleep disturbance, nasal steroids improve the subjective quality of sleep, however, although they maybe be useful as an adjunct for patients with mild OSA, they are an inadequate treatment for most OSA patients.

Decongestants

Randomised controlled trials

Three RCTs have been performed on the use of nasal decongestants (oxymetazoline) in OSA: In the first of these studies [50] the decongestant was combined with an internal nasal valve dilator, in the second one with an external dilator (Breath Right ™) [51] while a more recent study assessed the effect of decongestant alone [52]. The characteristics and results of the studies are also presented in Table 2. Two of the three RCTs showed no change in AHI and sleep architecture, while the study by McLean showed a modest decrease in AHI of limited clinical significance but no improvement in sleep quality or daytime somnolence. On the other hand, the study by Clarenbach showed no improvement in either subjective or objective indices of AHI. However, it did show that at the time of maximal effect of oxymetazoline there was a significant reduction in AHI, while the study by Kerr demonstrated subjective improvements in sleep quality.

Taken together, these results would show that although nasal decongestants with or without nasal dilators are not effective in the management of OSA (no improvement in sleepiness or AHI). In any case, their use is limited for only a few days, and hence, they could never be advocated for the management of OSA.

Leukotriene antagonists

A randomised double-blind crossover trial [53] assessing at the effects of montelukast on 31 patients with persistent allergic rhinitis and sleep disturbances found a significant effect of this leukotriene antagonist in reducing daytime somnolence as measured by Epworth sleepiness scale. However, none of the patients underwent polysomnography and this result has not been replicated in any other studies.

Nasal dilators

These devices increase the ability to breathe through the nose by dilating the narrow nasal valve area. There are two nasal dilators available: an externally applied Breathe Right^® (CNS Inc; Bloomington, MN, USA) and an internal device Nozovent^® (Prevancure AB, Sweden). Four randomised non-blinded studies have been conducted with these devices and an improvement in snoring has been noted in three of them [54–57], but improvement in objective sleep parameters in only one study [54]. In this last study, however, at, [54] only patients with mild OSA were recruited, while the AHI decreased from 18 to 6.4 with no effect on daytime sleepiness. In all other studies no effects on AHI or daytime sleepiness was found. We feel that nasal dilators are generally not recommended as a primary treatment in patients with OSA but may be beneficial in simple snorers with nasal valve collapse. Their lack of side effects and their price makes them in any case worthy of trial in selected patients. If they help in improving symptoms then it may be worthwhile for the patient to be considered for definitive nasal valve surgery.

Surgical treatment

As primary treatment

Nasal surgery is usually conducted to alter structural abnormalities present in primary snorers complaining of nasal obstruction in addition to snoring. There is another group of patients that may present to the rhinologist to improve the efficacy of their main treatment option of nasal continuous positive airway pressure (CPAP). Surgical procedures performed for SRBD include septoplasty/septorhinoplasty, functional endoscopic sinus surgery, turbinate reduction and nasal valve surgery.

Studies published in the 1980s and 1990s on effects of septoplasty on snoring demonstrated reduction in snoring by 50–75% [58–60]. In these studies, however, surgical outcomes were measured subjectively using questionnaires or visual analogue scales. Series, assessing the efficacy of nasal surgery (septoplasty, turbinectomy, and polypectomy) for OSA in a non-randomised study [61], suggested that normal cephalometry values of posterior airway space and mandibular plane to hyoid bone distances predicted surgical success. However, a more recent study by Virkkula et al. [62] suggested that snoring is not relieved by nasal surgery (septoplasty, septorhinoplasty and turbinate reduction surgery) despite an improvement in nasal resistance. This study conducted on forty Finnish patients presenting with snoring looked at the outcomes objectively using rhinomanometry, polysomnography and snoring intensity index. They concluded that the snoring time and intensity did not improve significantly in their patients, and that normal cephalometry did not predict a good response. In contrast to this Finnish study, studies from Korea [63] and Japan [64] assessing a different ethnic group showed a significant improvement in sleep parameters. This may appear to be the case if p values are examined (e.g. reduction of the respiratory disturbance index (RDI) from 39 preoperatively to 29.4 postoperatively giving a p value of 0.0001 as reported by Kim et al. [63]) but closer analysis of the study casts doubts on the clinical significance of this drop, if Sher’s criteria (reduction of more than 50% in RDI or AHI or the actual value to be <20) are applied [65].

Li et al. [66, 67] addressed recently the role of nasal surgery in patients with snoring and OSA from two different perspectives. First, they looked at the efficacy of nasal surgery to relieve snoring [66] and tried to identify predictive factors concluding that the tonsil size affected the outcome of nasal surgery for snoring. Secondly, they looked at the important issue of improvement in QoL after nasal surgery alone for patients with OSA and nasal obstruction [67]. In this study, they evaluated QoL using generic and disease specific questionnaires. They utilised the short-form health survey (SF 36), snore outcome survey and a separate spouse/bed partner survey. They concluded that by correcting an obstructed nasal airway they were able to significantly improve disease specific and generic QoL thus, substantiating the role of nasal surgery in treating these patients. However, in spite of the significant improvement noted in QoL parameters, disappointingly, there was no statistically significant improvement in the objective polysomnographic data. This discrepancy between objective and subjective results is shared by numerous other similar studies following nasal surgery alone for SRBD. Verse et al. [68] studied a cohort of 26 patients of whom 19 had OSA and 7 were simple snorers. A variety of nasal surgical procedures including septorhinoplasty, septoplasty, sinus surgery and nasal valve surgery were carried out. They concluded that although nasal surgery significantly improved sleep quality and daytime somnolence, the surgical response rate in the apnoeic group was in the region of 15% based on objective parameters (AHI). Four of their patients had worsening of OSA in spite of improving arousal index in some of these. This paradoxical effect can be explained by the so-called “first night effect” (when the patient has the initial, preoperative, sleep study for the first time, he does not sleep well and as a result the study it may not reflect the true severity of the SRBD; but with the subsequent postoperative sleep study the patient is already accustomed to the attachment of various leads and hence, the recording on this occasion reflects more accurately the severity of the problem).

Morinaga et al. [69] assessed the way in which pharyngeal morphology affected the outcome of nasal surgery in patients with OSA and nasal obstruction. The pharyngeal morphological features they looked at included tonsil size, Mallampati score, narrowness of fauces and the retroglossal dimension. They concluded that a favourable surgical outcome was seen in individuals who had a high-positioned soft palate and/or in those with a wide retroglossal space. Unlike Li et al. [66] they did not feel that the tonsil size affected the outcome of nasal surgery. However, the most important, and only randomised control trial was performed by the group of Koutsourelakis in Athens in 2007 [70], who assigned 49 patients with OSA and deviated nasal septum to either septoplasty or sham surgery and found that despite improvements in nasal patency as measured subjectively and objectively, there was no change in AHI or daytime sleepiness as assessed by Epworth Sleepiness Scale. Interestingly, in the surgical group there were 4 (14.8%) responders (using Sher’s criteria of reduction of AHI by more than 50%), however, only one patient was disease-free (AHI < 5). In conclusion, nasal surgery may improve QoL and snoring in a subgroup of patients with mild SDB and septal deviation. Although nasal surgery is certainly not an effective general treatment for OSA, further studies may better define carefully selected subgroups in which it may be of benefit.

As adjunctive to CPAP

The second group of patients that may be considered for nasal surgery are those who have failed CPAP therapy. The treatment of choice for moderate or severe OSA is CPAP but unfortunately it is frequently poorly tolerated with compliance rates less than 70% [71]. One of the reasons that patients may find CPAP so uncomfortable is either pre-existing structural nasal obstruction or CPAP-induced rhinitis. More than 50% of CPAP users complain of significant nasal symptoms, including nasal congestion, rhinorrhea, nasal dryness and sneezing [72]. Thus, it is vital that patients who do not comply with or adhere poorly to CPAP therapy should undergo detailed evaluation of their upper airway to identify obstructive pathology that may be surgically correctable. This may lead to a reduction in the CPAP pressure and, therefore, improve the compliance of this form of therapy. Powell [73] demonstrated this in a group of CPAP patients undergoing radiofrequency turbinate reduction. Patients in this study reported a subjective improvement in nasal obstruction which in turn was linked to improved CPAP use. Similarly, Friedman et al. [74] showed a significant decrease in CPAP titration levels following nasal surgery. In this study, reduction of pressure requirement for CPAP therapy was noted in patients with mild, moderate and severe OSA. The mean reduction of CPAP titration level was from 9.3 cmH₂O preoperatively to 6.7 cmH₂O postoperatively. This reduction in pressure would certainly help in improving the CPAP compliance.

Conclusion

It is now well recognised that improving nasal resistance medically, surgically or with the use of dilators can improve sleep quality; however, significant improvement in objective sleep parameters remain to be proven. Although there is no role for nasal surgery as single treatment for OSA, it is quite useful in improving symptoms in simple snorers and potentially useful as part of multilevel surgery in many patients with SRBD. In CPAP failures if upper airway evaluation demonstrates an obstructive nasal passage then treating this certainly improves CPAP compliance and adherence. In general, patients who responds positively to medical treatment or nasal dilators may be candidates for nasal surgical intervention, taking into account the limitations described.

Key points

1. Mechanisms through which nasal obstruction can lead or contribute to sleep apnoeas include the Starling resistor model, shunting of airflow through an unstable oral airway, blocking of the nasal respiratory reflex and reduced NO production and delivery.

2. Patients with self-reported nocturnal nasal obstruction are up to threefold more likely to snore and suffer from daytime somnolence.

3. Nasal steroids have been proven to improve subjective quality of sleep in patients with allergic rhinitis, but are not an effective treatment for adults with OSA.

4. Surgery to improve nasal patency is not indicated as primary treatment in patients with OSA, however, in selected patients with simple snoring it may reduce snoring and improve QoL.

5. In patients with OSA and nasal obstruction using CPAP, nasal surgery may reduce pressure requirements and improve compliance.